Vaxxinity, Inc. (VAXX)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Oct 2, 2026, 4:00 PM EST
Vaxxinity Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
12.68K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 66.00K | -491.00K | -88.15% |
| Dec 31, 2020 | 557.00K | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ObsEva | 19.64M |
| GeneLink | 1.58M |
| Trevena | 546.00K |
| Syros Pharmaceuticals | 386.00K |
| Bioasis Technologies | 199.01K |
| Navidea Biopharmaceuticals | 610.00 |
Vaxxinity News
- 2 years ago - Vaxxinity’s Parkinson’s candidate UB-312 demonstrates efficacy in publication - TheFly
- 2 years ago - Vaxxinity UB-312 Parkinson's Trial Results Published in Nature Medicine - GlobeNewsWire
- 2 years ago - Vaxxinity Issues Shareholder Letter - GlobeNewsWire
- 2 years ago - Vaxxinity to voluntarily delist, deregister its Class A common stock - TheFly
- 2 years ago - Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - GlobeNewsWire
- 2 years ago - Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewsWire
- 2 years ago - Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 years ago - Vaxxinity Annual report: Q4 2023 - Filings